New US subgroup data for Jascayd in idiopathic and progressive pulmonary fibrosis (IPF/PPF) is reinforcing the industry shift toward combination antifibrotic therapy in fibrotic lung disease management. Findings suggest the therapy can deliver meaningful clinical benefit alongside existing standard-of-care treatments, strengthening its commercial positioning as competitive intensity accelerates across the evolving pulmonary fibrosis treatment landscape, according to GlobalData, a leading intelligence and productivity platform.

At the 2026 American Thoracic Society (ATS) International Conference, Boehringer Ingelheim (BI) presented US subgroup data from the pooled Phase III FIBRONEER-IPF and FIBRONEER-ILD trials evaluating Jascayd (nerandomilast) in IPF and progressive pulmonary fibrosis (PPF). The timing follows Jascayd’s Q4 2025 US approval and reflects BI’s strategy to strengthen its market-specific evidence base as competition intensifies across the fibrotic lung disease landscape globally.

Jascayd, an oral PDE4B inhibitor with antifibrotic and immunomodulatory activity, previously demonstrated significant reductions in FVC decline across both pivotal trials. The ATS analysis focused on 332 US patients from the pooled 2,344-patient dataset, many of whom were already receiving background antifibrotic therapy, reinforcing Jascayd’s potential positioning in combination treatment strategies within the commercially significant US pulmonary fibrosis market.

Connor Daniels, Healthcare Analyst at GlobalData, comments: “This was critical as it helped position Jascayd not only as a potential monotherapy, but also as an adjunct therapy capable of delivering benefit on top of the current standard of care.”

The key opinion leaders (KOLs) previously interviewed by GlobalData noted that they consider combination therapy to be the future for both IPF and PPF treatment. Jascayd’s approval in both the monotherapy and combination settings, with pirfenidone per the FDA label, in the US is the first step towards this in the treatment paradigm.

Efficacy in US patients mirrored the broader trial population, with the 18mg dose showing stronger reductions in FVC decline and favorable trends across exacerbation, hospitalization, and mortality endpoints. Safety remained broadly manageable, although diarrhea was more frequent with nerandomilast versus placebo, highlighting an important tolerability consideration in clinical practice.

Daniels adds: “This finding will require careful management in clinical practice and clear communication in prescriber education, especially because KOLs previously interviewed by GlobalData stated that gastrointestinal side effects were the predominant reason for reduced compliance with both nintedanib and pirfenidone.”

The poster’s strategic significance extends beyond the data itself. Boehringer Ingelheim is positioning Jascayd alongside Ofev to establish a dual-mechanism antifibrotic franchise in IPF and PPF, while defending its pulmonary leadership ahead of Ofev’s 2029 US patent expiry. The move comes as competition intensifies, with therapies including United Therapeutics’ Tyvaso and Bristol Myers Squibb’s admilparant advancing through late-stage development. By presenting robust US-specific evidence, Boehringer Ingelheim is strengthening physician and payer confidence before rival agents gain market traction.

Daniels concludes: “For Boehringer Ingelheim, the imperative now is to translate this evidence into rapid commercial uptake, leveraging physician familiarity with its existing antifibrotic franchise and the combination therapy narrative to defend its market leadership as the fibrotic lung disease space becomes increasingly competitive.”